Literature DB >> 30004690

An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Steven K Albanese1,2, Daniel L Parton2, Mehtap Işık2,3, Lucelenie Rodríguez-Laureano2, Sonya M Hanson2, Julie M Behr2,4, Scott Gradia5, Chris Jeans5, Nicholas M Levinson6, Markus A Seeliger7, John D Chodera2.   

Abstract

Kinases play a critical role in cellular signaling and are dysregulated in a number of diseases, such as cancer, diabetes, and neurodegeneration. Therapeutics targeting kinases currently account for roughly 50% of cancer drug discovery efforts. The ability to explore human kinase biochemistry and biophysics in the laboratory is essential to designing selective inhibitors and studying drug resistance. Bacterial expression systems are superior to insect or mammalian cells in terms of simplicity and cost effectiveness but have historically struggled with human kinase expression. Following the discovery that phosphatase coexpression produced high yields of Src and Abl kinase domains in bacteria, we have generated a library of 52 His-tagged human kinase domain constructs that express above 2 μg/mL of culture in an automated bacterial expression system utilizing phosphatase coexpression (YopH for Tyr kinases and lambda for Ser/Thr kinases). Here, we report a structural bioinformatics approach to identifying kinase domain constructs previously expressed in bacteria and likely to express well in our protocol, experiments demonstrating our simple construct selection strategy selects constructs with good expression yields in a test of 84 potential kinase domain boundaries for Abl, and yields from a high-throughput expression screen of 96 human kinase constructs. Using a fluorescence-based thermostability assay and a fluorescent ATP-competitive inhibitor, we show that the highest-expressing kinases are folded and have well-formed ATP binding sites. We also demonstrate that these constructs can enable characterization of clinical mutations by expressing a panel of 48 Src and 46 Abl mutations. The wild-type kinase construct library is available publicly via Addgene.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30004690      PMCID: PMC6081246          DOI: 10.1021/acs.biochem.7b01081

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  45 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.

Authors:  Tatsuya Horio; Tomohiro Hamasaki; Toshihiko Inoue; Tatsushi Wakayama; Shinsaku Itou; Haruna Naito; Tetsuo Asaki; Hiroki Hayase; Tomoko Niwa
Journal:  Bioorg Med Chem Lett       Date:  2007-03-03       Impact factor: 2.823

3.  Combining the polymerase incomplete primer extension method for cloning and mutagenesis with microscreening to accelerate structural genomics efforts.

Authors:  Heath E Klock; Eric J Koesema; Mark W Knuth; Scott A Lesley
Journal:  Proteins       Date:  2008-05-01

Review 4.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

5.  High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.

Authors:  Markus A Seeliger; Matthew Young; M Nidanie Henderson; Patricia Pellicena; David S King; Arnold M Falick; John Kuriyan
Journal:  Protein Sci       Date:  2005-10-31       Impact factor: 6.725

6.  Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Matthew A Young; Klaus Scheffzek; Darren Veach; William Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

7.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

8.  UniProt: the universal protein knowledgebase.

Authors: 
Journal:  Nucleic Acids Res       Date:  2016-11-29       Impact factor: 16.971

Review 9.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 10.  A comprehensive map of molecular drug targets.

Authors:  Rita Santos; Oleg Ursu; Anna Gaulton; A Patrícia Bento; Ramesh S Donadi; Cristian G Bologa; Anneli Karlsson; Bissan Al-Lazikani; Anne Hersey; Tudor I Oprea; John P Overington
Journal:  Nat Rev Drug Discov       Date:  2016-12-02       Impact factor: 84.694

View more
  9 in total

1.  A Tale of Two Tyrosines.

Authors:  Robert B Best
Journal:  Biophys J       Date:  2020-10-14       Impact factor: 4.033

2.  Di-phosphorylated BAF shows altered structural dynamics and binding to DNA, but interacts with its nuclear envelope partners.

Authors:  Agathe Marcelot; Ambre Petitalot; Virginie Ropars; Marie-Hélène Le Du; Camille Samson; Stevens Dubois; Guillaume Hoffmann; Simona Miron; Philippe Cuniasse; Jose Antonio Marquez; Robert Thai; François-Xavier Theillet; Sophie Zinn-Justin
Journal:  Nucleic Acids Res       Date:  2021-04-19       Impact factor: 16.971

3.  Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.

Authors:  Agatha Lyczek; Benedict-Tilman Berger; Aziz M Rangwala; YiTing Paung; Jessica Tom; Hannah Philipose; Jiaye Guo; Steven K Albanese; Matthew B Robers; Stefan Knapp; John D Chodera; Markus A Seeliger
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-16       Impact factor: 11.205

4.  De novo design of tyrosine and serine kinase-driven protein switches.

Authors:  Nicholas B Woodall; Zara Weinberg; Jesslyn Park; Florian Busch; Richard S Johnson; Mikayla J Feldbauer; Michael Murphy; Maggie Ahlrichs; Issa Yousif; Michael J MacCoss; Vicki H Wysocki; Hana El-Samad; David Baker
Journal:  Nat Struct Mol Biol       Date:  2021-09-13       Impact factor: 18.361

5.  Chemoenzymatic Semi-synthesis Enables Efficient Production of Isotopically Labeled α-Synuclein with Site-Specific Tyrosine Phosphorylation.

Authors:  Buyan Pan; Joo Hyung Park; Trudy Ramlall; David Eliezer; Elizabeth Rhoades; E James Petersson
Journal:  Chembiochem       Date:  2021-01-29       Impact factor: 3.164

6.  Genomic variants within chromosome 14q32.32 regulate bone mass through MARK3 signaling in osteoblasts.

Authors:  Qian Zhang; Larry D Mesner; Gina M Calabrese; Naomi Dirckx; Zhu Li; Angela Verardo; Qian Yang; Robert J Tower; Marie-Claude Faugere; Charles R Farber; Thomas L Clemens
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 19.456

7.  The hypervariable region of atlastin-1 is a site for intrinsic and extrinsic regulation.

Authors:  Carolyn M Kelly; Laura J Byrnes; Niharika Neela; Holger Sondermann; John P O'Donnell
Journal:  J Cell Biol       Date:  2021-09-21       Impact factor: 10.539

8.  The BAF A12T mutation disrupts lamin A/C interaction, impairing robust repair of nuclear envelope ruptures in Nestor-Guillermo progeria syndrome cells.

Authors:  Anne Janssen; Agathe Marcelot; Sophia Breusegem; Pierre Legrand; Sophie Zinn-Justin; Delphine Larrieu
Journal:  Nucleic Acids Res       Date:  2022-08-30       Impact factor: 19.160

Review 9.  Intrinsically Fluorescent Anti-Cancer Drugs.

Authors:  Md Lutful Kabir; Feng Wang; Andrew H A Clayton
Journal:  Biology (Basel)       Date:  2022-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.